--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-21-110678" form_type: "8-K" ticker: "HUMA" cik: "0001818382" company_name: "Humacyte, Inc." filed_at: "2021-08-30T23:59:59+00:00" generated_at: "2026-06-29T07:05:48.888317+00:00" event_type: "m_and_a" sentiment: "positive" materiality_score: 0.95 calibrated_materiality_score: 0.95 confidence: "high" source: SEC EDGAR --- # Humacyte completes SPAC merger; begins trading as HUMA; $175M PIPE investment closed ## Summary - Business combination closed Aug 26, 2021; Legacy Humacyte becomes wholly owned subsidiary Humacyte Global, Inc. - PIPE investors purchased 17.5M shares at $10.00/share for aggregate $175M; shares issued pre-effective time. - Exchange ratio: 0.26260 new Humacyte shares per Legacy Humacyte common share; options/warrants adjusted similarly. - One-year lock-up on most shares; early release if stock hits $15 for 20 of 30 days after 180 days. - Company plans BLA submission for vascular trauma in 2022, AV access in 2023; ~435 patients implanted as of May 2021. ## SEC filing metadata - accession: 0001104659-21-110678 - form_type: 8-K - ticker: HUMA - cik: 0001818382 - company_name: Humacyte, Inc. - filed_at: 2021-08-30T23:59:59+00:00 - event_type: m_and_a - sentiment: positive - materiality_score: 0.95 - calibrated_materiality_score: 0.95 - confidence: high - sec_items: 1.01, 2.01, 5.06, 9.01, 5.02, 3.02, 4.01, 3.03, 5.01, 5.03, 7.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/tm2126013d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-21-110678 - JSON: https://secwatch.observer/filing/0001104659-21-110678.json - Plain text: https://secwatch.observer/filing/0001104659-21-110678.txt ## Key facts - Executive change Heather Prichard was appointed as Chief Operating Officer at Humacyte, Inc.. - Action: appointed - Role: Chief Operating Officer source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - Executive change Laura E. Niklason was appointed as President, Chief Executive Officer and Director at Humacyte, Inc.. - Action: appointed - Role: President, Chief Executive Officer and Director source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - Executive change Dale A. Sander was appointed as Chief Financial Officer, Chief Corporate Development Officer and Treasurer at Humacyte, Inc.. - Action: appointed - Role: Chief Financial Officer, Chief Corporate Development Officer and Treasurer source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - Executive change William (B.J.) Scheessele was appointed as Chief Commercial Officer at Humacyte, Inc.. - Action: appointed - Role: Chief Commercial Officer source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - Executive change Jeffrey H. Lawson was appointed as Chief Surgical Officer and Director at Humacyte, Inc.. - Action: appointed - Role: Chief Surgical Officer and Director source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - Executive change William Tente was appointed as Chief Regulatory Officer at Humacyte, Inc.. - Action: appointed - Role: Chief Regulatory Officer source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm - Executive change Kiernan T. DeAngelis was appointed as Chief Medical Officer at Humacyte, Inc.. - Action: appointed - Role: Chief Medical Officer source text: Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.